• 1
    Visser O, Coebergh JWW, Schouten LJ. Incidence of cancer in the Netherlands 1992. Fourth report of The Netherlands Cancer Registry.
  • 2
    Schroder FH. Screening, early detection and treatment of prostate cancer: A European view. Urology 1995; 46: 6270.
  • 3
    Schroder FH, Denis LJ, Kirkels WJ et al. European randomised study of screening for prostate cancer (progress report of Antwerp and Rotterdam pilot studies). Cancer 1995; 76: 12934.
  • 4
    Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 115661.
  • 5
    Brawer MK. Prostatic intraepithelial neoplasia and prostate specific antigen. Urology 1989; 34: 625.
  • 6
    Robles JM, Morell A, Redorta JP et al. Clinical behaviour of prostate specific antigen and prostatic acid phosphatase: A comparative study. Eur Urol 1988; 14: 3606.
  • 7
    Glenski WJ, Malek RS, Myrtle JF, Oesterling JE. Sustained substantially increased concentration of prostate specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario. Mayo Clin Proc 1992; 67: 24952.
  • 8
    Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 90723.
  • 9
    Spencer JA, Alexander AA, Gomella L et al. Clinical and US findings in prostate cancer: Patients with normal prostate specific antigen levels. Radiology 1993; 189: 38993.
  • 10
    Lee F, Gray JM, McCleary RD et al. Transrectal ultrasound in the diagnosis of prostate cancer: location echogenicity histopathology and staging. Prostate 1985; 7: 11729.
  • 11
    Nourusis MJ. SPSS/PC + Advanced Statistics 4.0. Chicago: SPSS Inc; 1990; Chap. 1, blb37.
  • 12
    Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 56177.
  • 13
    Green D, Swets J. Signal Detection Theory and Psychognosics. New York: John Wiley, 1966; 459.
  • 14
    Benson MC, Whang IS, Pantuck A et al. Prostate specific antigen density: A means of distinguishing BPH and prostate cancer. J Urol 1992; 147: 81516.
  • 15
    Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community based population of healthy men: establishment of age specific reference ranges. JAMA 1993; 270: 8604.
  • 16
    Bangma Chr H, Rietbergen JBW, Schroder FH. PSA as a screening test: Experience in the Netherlands. Urol Clin North Am 1996, in press.
  • 17
    Bangma Chr H, Rietbergen JBW, Kranse R, Blijenberg BG et al. The free/total prostate specific antigen ratio improves the specificity of PSA in screening prostate cancer in the general population. J Urol 1997: in press.
  • 18
    Oesterling JE, Jacobsen SJ, Cooner WJ. The use of age specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995; 153: 11603.